Literature DB >> 19901099

Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

Sandrine J Faivre, Mohamed Bouattour, Chantal Dreyer, Eric Raymond.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19901099     DOI： 10.1200/JCO.2009.25.0670

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

Review 1.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

2.  Liver cancer: Targeted future options.

Authors:  Andreas Pircher; Michael Medinger; Joachim Drevs
Journal:  World J Hepatol       Date:  2011-02-27

3.  Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Maxime Ronot; Mohamed Bouattour; Johanna Wassermann; Onorina Bruno; Chantal Dreyer; Béatrice Larroque; Laurent Castera; Valérie Vilgrain; Jacques Belghiti; Eric Raymond; Sandrine Faivre
Journal:  Oncologist       Date:  2014-03-20

4.  Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

Authors:  Chantal Dreyer; Marie-Paule Sablin; Mohamed Bouattour; Cindy Neuzillet; Maxime Ronot; Safi Dokmak; Jacques Belghiti; Nathalie Guedj; Valérie Paradis; Eric Raymond; Sandrine Faivre
Journal:  World J Hepatol       Date:  2015-04-28

Review 5.  Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Authors:  Kyrre E Emblem; Christian T Farrar; Elizabeth R Gerstner; Tracy T Batchelor; Ronald J H Borra; Bruce R Rosen; A Gregory Sorensen; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

6.  Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Authors:  Dai Liu; Guangfu Li; Diego M Avella; Eric T Kimchi; Jussuf T Kaifi; Mark P Rubinstein; E Ramsay Camp; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 8.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

9.  Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

Authors:  Sandrine Faivre; Maxime Ronot; Chantal Dreyer; Camille Serrate; Olivia Hentic; Mohamed Bouattour; Onorina Bruno; Anne Couvelard; Valérie Vilgrain; Eric Raymond
Journal:  Target Oncol       Date:  2012-05-15       Impact factor: 4.493

10.  Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

Authors:  Sadahisa Ogasawara; Fumihiko Kanai; Yoshihiko Ooka; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Tetsuhiro Chiba; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2013-02-12       Impact factor: 9.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.